Day: May 14, 2026

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB’s Venture Debt Program

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

First-of-its-kind partnership expands NeuroStar platform capabilities with advanced visualization technology designed to address evolving provider needs and support more personalized...

CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress

Oversubscribed $22.5 million financing anticipated to enable CNS Pharmaceuticals to acquire differentiated, clinical-stage assets with identifiable near-term value-inflection catalysts, aligned...

Israel’s Digital Health Stress Test: AI, Cybersecurity, and Wartime Care Redefine the 2026 Healthcare IT Market

New Black Book Research report analyzes Israel's EHR/EMR maturity, national health information exchange, AI in medicine, hospital cybersecurity, wartime continuity,...

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

John Cena Tarsus and John Cena are partnering to raise awareness of Demodex blepharitis, a common eyelid disease affecting approximately...

Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026

Recent transition to the Full Market Release has already resulted in increased revenue for the current Q2, which has already...

error: Content is protected !!